Literature DB >> 9414030

Rolipram, a phosphodiesterase-4-selective inhibitor, promotes the survival of cultured rat dopaminergic neurons.

N Yamashita1, A Hayashi, J Baba, A Sawa.   

Abstract

We evaluated the effects of rolipram, a selective inhibitor of phosphodiesterase (PDE) 4, on the survival of dopaminergic neurons in 13-day culture. Rolipram did not affect the survival of dopaminergic neurons in the absence of forskolin, but significantly enhanced the survival of dopaminergic neurons in the presence of 10(-5) M forskolin in a concentration-dependent manner (10(-8) - 10(-5) M). Rolipram also enhanced the neurotrophic effect of forskolin on total neurons including dopaminergic and non-dopaminergic neurons at a high concentration (10(-5) M), but did not affect the survival of cells containing glutamate or gamma-aminobutylic acid. A non-selective PDE inhibitor, 1-isobutyl-3-methylxanthine, caused a marked increase of dopaminergic neurons, whereas selective inhibitors of PDE2 and PDE3 showed far weaker effects. A PDE1 inhibitor, on the other hand, caused non-specific cell death in the presence or absence of forskolin. These findings suggest that rolipram has a potential to enhance the survival of dopaminergic neurons selectively by way of PDE4 inhibition.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9414030     DOI: 10.1254/jjp.75.155

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN: 0021-5198


  10 in total

Review 1.  PDE4 as a target for cognition enhancement.

Authors:  Wito Richter; Frank S Menniti; Han-Ting Zhang; Marco Conti
Journal:  Expert Opin Ther Targets       Date:  2013-07-25       Impact factor: 6.902

2.  The phosphodiesterase-4 inhibitor roflumilast decreases ethanol consumption in C57BL/6J mice.

Authors:  Xin Liu; Pi-Da Hao; Ming-Feng Yang; Jing-Yi Sun; Lei-Lei Mao; Cun-Dong Fan; Zong-Yong Zhang; Da-Wei Li; Xiao-Yi Yang; Bao-Liang Sun; Han-Ting Zhang
Journal:  Psychopharmacology (Berl)       Date:  2017-05-06       Impact factor: 4.530

Review 3.  Can Cyclic Nucleotide Phosphodiesterase Inhibitors Be Drugs for Parkinson's Disease?

Authors:  Dominic Ngima Nthenge-Ngumbau; Kochupurackal P Mohanakumar
Journal:  Mol Neurobiol       Date:  2017-01-06       Impact factor: 5.590

Review 4.  Inhibition of phosphodiesterases as a strategy to achieve neuroprotection in Huntington's disease.

Authors:  Antonella Cardinale; Francesca R Fusco
Journal:  CNS Neurosci Ther       Date:  2018-03-03       Impact factor: 5.243

Review 5.  Caffeine provokes adverse interactions with 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') and related psychostimulants: mechanisms and mediators.

Authors:  N Vanattou-Saïfoudine; R McNamara; A Harkin
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

6.  Roflupram protects against rotenone-induced neurotoxicity and facilitates α-synuclein degradation in Parkinson's disease models.

Authors:  Wen-Li Dong; Jia-Hong Zhong; Yun-Qing Chen; Jin-Feng Xie; Yun-Yun Qin; Jiang-Ping Xu; Ning-Bo Cai; Meng-Fan Li; Lu Liu; Hai-Tao Wang
Journal:  Acta Pharmacol Sin       Date:  2021-09-16       Impact factor: 6.150

7.  Distinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatum.

Authors:  Akinori Nishi; Mahomi Kuroiwa; Diane B Miller; James P O'Callaghan; Helen S Bateup; Takahide Shuto; Naoki Sotogaku; Takaichi Fukuda; Nathaniel Heintz; Paul Greengard; Gretchen L Snyder
Journal:  J Neurosci       Date:  2008-10-15       Impact factor: 6.167

Review 8.  Phosphodiesterase Inhibitors as a Therapeutic Approach to Neuroprotection and Repair.

Authors:  Eric P Knott; Mazen Assi; Sudheendra N R Rao; Mousumi Ghosh; Damien D Pearse
Journal:  Int J Mol Sci       Date:  2017-03-24       Impact factor: 5.923

9.  Phosphodiesterase Inhibition and Regulation of Dopaminergic Frontal and Striatal Functioning: Clinical Implications.

Authors:  Pim R A Heckman; Marlies A van Duinen; Eva P P Bollen; Akinori Nishi; Lawrence P Wennogle; Arjan Blokland; Jos Prickaerts
Journal:  Int J Neuropsychopharmacol       Date:  2016-04-02       Impact factor: 5.176

10.  Inhibition of phosphodiesterase 4 by FCPR16 protects SH-SY5Y cells against MPP+-induced decline of mitochondrial membrane potential and oxidative stress.

Authors:  Jiahong Zhong; Hui Yu; Chang Huang; Qiuping Zhong; Yaping Chen; Jinfeng Xie; Zhongzhen Zhou; Jiangping Xu; Haitao Wang
Journal:  Redox Biol       Date:  2018-02-14       Impact factor: 11.799

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.